What if Alzheimer’s disease left its mark on the embryo? Khadijeh Shabani and her colleagues from the “Brain Development” team led by Bassem Hassan (Inserm) at Paris Brain Institute show that the amyloid precursor protein (APP) has a specific biological role during neurodevelopment. It delays the onset of neurogenesis, i.e., the differentiation of stem cells into different nerve cell lineages. Subtle disruptions of this mechanism could, in some individuals, induce vulnerabilities that only become apparent in adulthood after decades of biological stress. Alzheimer’s disease could then be considered a neurodevelopmental disorder… with a particularly late onset. These results are published in Science Advances.
In the cerebral cortex, neurogenesis – the formation of neural cells from stem cells – begins in the fetus from 5 weeks gestation and is almost complete by 28 weeks. It is a complex process with finely tuned mechanisms.
Until now, researchers did not know how this balance between stem cell proliferation and differentiation into several cell types was regulated. Above all, they ignored whether the exceptionally long-time span of human neurogenesis could pave the way for vulnerabilities specific to our species, such as neurodegenerative diseases. To better understand how our brains are shaped during this crucial period, researchers from the “Brain Development” team led by Bassem Hassan at Paris Brain Institute investigated.
APP, conductor of neuronal production
In many species, APP is involved in various biological processes, such as repairing cerebral lesions, orchestrating cellular response after oxygen deprivation, or controlling brain plasticity. It is highly expressed during the differentiation and migration of cortical neurons, suggesting an essential role in neurogenesis. But what about humans?
To track APP expression during human brain development, the researchers used cell sequencing data obtained from the fetus at ten weeks and then 18 weeks gestation. They observed that the protein was first expressed in 6 cell types, then, a few weeks later, in no less than 16 cell types. They then used the CRISPR-Cas9 genetic scissors technique to produce neural stem cells in which APP was not expressed. They then compared these genetically modified cells with cells obtained in vivo.
Specifically, the team showed that APP was involved in two fined-tuned genetic mechanisms: on the one hand, canonical WNT signaling, which controls stem cell proliferation, and AP-1 activation, which triggers the production of new neurons. By acting on these two levers, APP is able to regulate the timing of neurogenesis.
Human neurogenesis, all too human
While the loss of APP strongly accelerates brain neurogenesis in humans, this is not the case in rodents.
What if the timing of human neurogenesis was directly linked to the mechanisms of neurodegeneration? Although neurodegenerative diseases are generally diagnosed between the ages of 40 and 60, researchers believe that clinical signs appear several decades after the onset of decline in certain neuronal connections. This loss of connectivity may itself reflect anomalies at a molecular scale present from childhood or even earlier.
Further studies will be needed to confirm that APP plays a central role in the neurodevelopmental disruptions that pave the way for Alzheimer’s disease. In which case, we could consider that:
Sources
Shabani K. et al. The temporal balance between self-renewal and differentiation of human1 neural stem cells requires the Amyloid Precursor Protein. Science advances (2023). DOI: 10.1126/sciadv.add5002.
Shabani K., Hassan B. The brain on time: links between development and neurodegeneration. Development (2023). DOI: 10.1242/dev.200397
Funding
This work was supported by the Investissements d’Avenir program, Paris Brain Institute–ICM core funding, a Sorbonne Université Emergence grant, a Neuro-Glia foundation grant, and the Roger De Spoelberch Prize.